22
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6668 |
SGC-CBP30
|
Epigenetic Reader Domain; Histone Acetyltransferase | Chromatin/Epigenetic |
SGC-CBP30 是高选择性CBP/p300溴结构域的有效抑制剂,对CBP 和p300的Kd 值分别为 21 和 32 nM。它强烈减少 Th17 细胞中 IL-17A 的分泌,具有抗炎作用。 | |||
T1159 |
Leflunomide
SU101,RS-34821,HWA486,来氟米特 |
Others; Dehydrogenase; AhR | Immunology/Inflammation; Metabolism; Others |
Leflunomide (HWA486) 是嘧啶合成抑制剂,能够抑制二氢乳清酸脱氢酶,具有抗风湿的活性。 | |||
T38362 |
Guselkumab
CNTO 1959 |
IL Receptor | Immunology/Inflammation |
Guselkumab (CNTO 1959) 是一种针对IL-23p19亚基的重组人IgG1单克隆抗体。Guselkumab 与人和食蟹猴IL-23结合,Kd 值分别为3.3和1.9 pmol/L。Guselkumab 对IL-23信号通路下游细胞因子的产生具有抑制作用,可用于银屑病关节炎的研究。 | |||
T76924 |
Efalizumab
Hu1124,HU 1124 |
Integrin | Cytoskeletal Signaling |
Efalizumab 是一种新型针对 T 细胞的有效调节剂,是人源化 LFA-1 α 亚基(CD11a)单克隆抗体。Efalizumab 对 T 细胞激活、皮肤T细胞运输和T细胞粘附到角质形成细胞有抑制作用,可用于研究斑块银屑病和银屑病关节炎。 | |||
T77677 |
12R-LOX-IN-2
|
Lipoxygenase | Metabolism |
12R-LOX-IN-2 是一种 12R-脂氧合酶 (12R-LOX) 的抑制剂。12R-LOX-IN-2 抑制咪喹莫特 (IMQ) 诱导银屑病角质形成细胞过度增殖,并抑制细胞集落形成。12R-LOX-IN-2 还降低 IMQ 诱导细胞中 Ki67 的蛋白水平和 IL-17A 的 mRNA 表达。12R-LOX-IN-2 可用于牛皮癣和其他皮肤相关炎症性疾病的研究。 | |||
T76778 |
Risankizumab
Risankizumab rzaa,SKYRIZI,ABBV 066,BI-655066 |
IL Receptor | Immunology/Inflammation |
Risankizumab (BI 655066) 是一种人源化靶向 IL-23 p19 亚基的 IgG 单克隆抗体(Kd <10 pM)。 Risankizumab 能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生,IC50 值为 2 pM。Risankizumab 可用于预防和治疗如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病类的免疫性和炎症性疾病。 | |||
T21043 |
Apremilast, (+/-)-
Apremilast (+/-)-, |
||
Apremilast, (+/-)-, is a small molecule inhibitor of phosphodiesterase 4 (PDE4) with oral activity. It is used to treat psoriatic arthritis. | |||
T77098 | Netakimab | ||
Netakimab为抗IL-17单克隆抗体。Nerelimomab适用于研究强直性脊柱炎、银屑病关节炎及中重度斑块状银屑病。 | |||
T76823 | Perakizumab | ||
Perakizumab (RG4934)为针对IL-17A(Interleukin Related)的人源化IgG1κ单克隆抗体。适用于自身免疫性疾病(例如银屑病关节炎)的研究。 | |||
T36525 |
IL-17 modulator 1 disodium
|
||
IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis[1]. | |||
T40106 | IL-17 modulator 1 | ||
IL-17 modulator 1 is an orally active small molecule. It is highly efficacious in modulating IL-17 and can effectively prevent, treat, or ameliorate various diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. | |||
T36611 |
(±)13-HODE
|
||
(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentration of 17 ng/mg.[1] | |||
T76840 | Vunakizumab | ||
Vunakizumab (Anti-Human IL17A Recombinant Antibody) 是一种重组的人源化 IgGκ 单克隆抗体,可以靶向 IL-17A 并抑制其与 IL-17受体的相互作用。Vunakizumab 可用于研究银屑病关节炎、强直性脊柱炎、多发性硬化症和炎症性关节炎等自身免疫性疾病。 | |||
T63558 | IRAK4-IN-21 | ||
IRAK4-IN-21 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂,能够作用于 IRAK4 (IC50: 5 nM) 和 TAK1 (IC50: 56 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用,其 IC50值为0.17 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病,如斑块状银屑病和银屑病关节炎。 | |||
T81331 |
QL-1200186
|
JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
QL-1200186为具备口服活性与选择性的TYK2抑制剂。经口服后,该药剂量依赖性抑制因interleukin-12刺激所诱导的interferon-γ产生,并在银屑病模型小鼠中显著改善皮肤病变状况。 | |||
T76872 | Neihulizumab | ||
Neihulizumab (ALTB-168) 是一种免疫检查点激动性抗体,可与人 CD162 (PSGL-1)结合,导致活化的 T 细胞下调。Neihulizumab 可用于类固醇难治性急性移植物抗宿主病 (SR-aGVHD)、银屑病、银屑病关节炎和溃疡性结肠炎的研究。 | |||
T76675 | Clazakizumab | ||
Clazakizumab是一种具有高亲和力和特异性的单克隆抗体,针对IL-6(白细胞介素-6)细胞因子。它可能对抑制COVID-19中因SARS-CoV-2引起的细胞因子反应有帮助。此外,Clazakizumab也被用于研究银屑病关节炎(PsA)和肾抗体介导的排斥反应。 | |||
T83457 | 12R-LOX-IN-1 | ||
12R-LOX-IN-1(Compound 4a)是一种效能为IC50: 28.25 μM的12R-LOX抑制剂。该化合物能够有效抑制Imiquimod诱导的银屑病角质形成细胞的异常增殖和集落形成能力,同时减少活性氧、Ki67、IL-17A、TNF-α和IL-6的生成,适用于抗银屑病研究。 | |||
T63559 | IRAK4-IN-22 | ||
IRAK4-IN-22 是选择性的、口服具有活力的、强效的 IRAK4 抑制剂,能够作用于 IRAK4 (IC50: 3 nM) 和 TAK1 (IC50: 17 nM)。IRAK4-IN-21 对 IL-23 的产生表现出有效的抑制作用,其 IC50值为0.10 μM。IRAK4-IN-21 能够用于研究自身免疫性疾病,如斑块状银屑病和银屑病关节炎。 | |||
T38309 |
LL-37 amide (trifluoroacetate salt)
|
||
LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions. It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection. LL-37 binds sheep erythrocytes coated with S. ... | |||
T36379 |
Halometasone
|
||
Halometasone is a synthetic corticosteroid.1,2Formulations containing halometasone have been used in the treatment of psoriasis vulgaris and eczematous dermatoses. 1.de la Brassine, M., Kint, A., Lachapelle, J.M., et al.Halomethasone (C 48.401-Ba) for the topical treatment of common dermatosesJ. Int. Med. Res.12(5)307-309(1984) 2.Zhu, J.-W., Wu, X.-J., Lu, Z.-F., et al.Role of VEGF receptors in normal and psoriatic human keratinocytes: Evidence from irradiation with different UV sourcesPLoS One8... | |||
T35451 |
β-Defensin-2 (human) (trifluoroacetate salt)
|
||
β-Defensin-2 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts.1It inhibits the growth of periodontopathogenic and cariogenic bacteria, includingP. gingivalisandS. salivarius.2β-Defensin-2 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes.3It also stimulates calcium mobilization, migration, and proliferation of keratinocytes whe... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1068 |
Dithranol
1,8,9-trihydroxyanthracene,cignoline,蒽林,Anthralin |
Others; DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair; Others |
Dithranol (cignoline) 是蒽醌衍生物,可破坏线粒体功能和结构,用于治疗皮肤病。 |